Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?

Research output: Contribution to journalArticlepeer-review

Abstract

In a multicenter, observational, propensity-score-weighted cohort of 249 adults with uncomplicated Pseudomonas aeruginosa bacteremia, patients receiving short-course (median, 9 days; interquartile range [IQR], 8-10) therapy had a similar odds of recurrent infection or death within 30 days as those receiving longer courses (median, 16 days; IQR, 14-17).

Original languageEnglish (US)
Pages (from-to)2011-2014
Number of pages4
JournalClinical Infectious Diseases
Volume69
Issue number11
DOIs
StatePublished - Nov 13 2019

Keywords

  • Pseudomonas aeruginosa
  • cefepime
  • gram-negative bacteremia
  • piperacillin-tazobactam
  • treatment duration

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?'. Together they form a unique fingerprint.

Cite this